🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gareth Griffiths

Cancer Research UK

ORCID: 0000-0002-9579-8021

Also affiliated with University Hospital Southampton NHS Foundation Trust, NIHR Evaluation Trials and Studies Coordinating Centre, Cancer Research UK Clinical Trials Unit, University of Southampton

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 4 papers. Top paper: “Immunocytochemical localization of β-COP to the ER-Golgi boundary and the TGN”.

Immunocytochemical localization of β-COP to the ER-Golgi boundary and the TGN

Journal of Cell Science(1995)10.1242/jcs.108.8.2839
N/A
0.729DataRank · unranked
128 citations

Rainer Pepperkok, Jacomine Krijnse Locker, Thomas E. Kreis, Gareth Griffiths

Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT

Health Technology Assessment(2021)10.3310/hta25310
N/A
0.354DataRank · unranked
5 citations

Jane Blazeby, Catharine Porter, Chris Hurt, Gareth Griffiths, Annmarie Nelson +12 more

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

medRxiv(2021)10.1101/2021.09.10.21263376
N/A
0DataRank · unranked
0 citations

Richard J. Fitzgerald, Geoffrey Saunders, Rebecca Lyon, Michael Fisher, Karen Martin +27 more

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

Nature Communications(2025)10.1038/s41467-025-61691-4
N/A
0DataRank · unranked
5 citations

Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings, Essa Y. Baitei +35 more